Regeneron Says It Expects Exemption From Proposed U.S. Drug Tariffs
Regeneron Pharmaceuticals said it expects to be left off a proposed U.S. tariff list aimed at drugmakers that have not finalized price-cut agreements with the administration. The company said it expects to announce a deal "in the near future" to reduce prescription costs for Medicaid and cash-paying patients, and remains the only one of 17 firms th…